Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CDIO
CDIO logo

CDIO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.940
Open
1.700
VWAP
1.84
Vol
77.66K
Mkt Cap
5.56M
Low
1.700
Amount
142.89K
EV/EBITDA(TTM)
--
Total Shares
2.96M
EV
722.96K
EV/OCF(TTM)
--
P/S(TTM)
170.40
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Show More

Events Timeline

(ET)
2025-12-03
08:50:00
Cardio Diagnostics Sets Final Payment Rate of $854 for Epi+Gen CHD and PrecisionCHD Tests
select
2025-07-22 (ET)
2025-07-22
09:13:48
Cardio Diagnostics gets CMS gapfill payment rates for cardiovascular tests
select
2025-07-08 (ET)
2025-07-08
09:17:19
Cardio Diagnostics, AGEPHA Pharma in deal for heart disease study
select
2025-06-10 (ET)
2025-06-10
08:56:06
Cardio Diagnostics secures Japanese patent for set of biomarkers
select
2025-05-29 (ET)
2025-05-29
08:41:00
Cardio Diagnostics regains compliance with Nasdaq
select
2025-05-08 (ET)
2025-05-08
08:40:45
Cardio Diagnostics announces 1-for-30 reverse stock split
select
2024-11-22 (ET)
2024-11-22
15:40:54
Cardio Diagnostics files to sell 1.24M shares of common stock for holders
select

News

Globenewswire
7.5
04-08Globenewswire
Cardio Diagnostics Partners with IBN to Enhance Communication Strategy
  • Strategic Partnership: Cardio Diagnostics Holdings Inc. has engaged IBN to enhance its corporate communications strategy, leveraging IBN's investor-focused distribution network to increase awareness in the cardiovascular disease prevention and detection sector, which is expected to attract more investor interest.
  • Technological Innovation: The company’s Epi+Gen CHD™ test, developed using artificial intelligence and genomics, assesses a patient's three-year risk of coronary heart disease events, representing a significant breakthrough in precision medicine that could transform traditional cardiovascular disease management.
  • Product Portfolio Expansion: With the introduction of PrecisionCHD™ and HeartRisk™, which aid in coronary heart disease detection and population-level cardiovascular risk assessment respectively, Cardio Diagnostics is enhancing its product line, increasing market competitiveness, and potentially driving sales growth.
  • Market Influence: IBN's extensive experience of over 20 years and partnerships with more than 500 clients will enable Cardio Diagnostics to leverage over 5,000 news outlets and social media platforms to expand its market influence and enhance brand recognition.
Newsfilter
7.5
04-08Newsfilter
Cardio Diagnostics Partners with IBN to Enhance Communication Strategy
  • Strategic Partnership: Cardio Diagnostics Holdings Inc. has engaged IBN to enhance its corporate communications strategy by leveraging IBN's investor-focused distribution network, which includes over 5,000 key syndication outlets, thereby increasing awareness in the cardiovascular disease prevention and detection sector.
  • Technological Innovation: The company utilizes artificial intelligence and genomics to develop blood tests, launching products like Epi+Gen CHD™ and PrecisionCHD™, which aid in assessing and managing coronary heart disease risk, thus advancing precision medicine.
  • Market Impact: By partnering with IBN, Cardio Diagnostics aims to expand its influence among investors and the public, capitalizing on IBN's 20 years of industry experience and millions of social media followers to drive future growth.
  • Product Portfolio: Cardio Diagnostics offers products such as HeartRisk™ and CardioInnovate360™, which not only provide individual and population-level cardiovascular risk assessments but also support the discovery and development of cardiovascular therapies, further solidifying its market position.
Benzinga
9.5
02-27Benzinga
Applied Optoelectronics Reports Strong Q4, Shares Surge
  • Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
  • Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
  • Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
  • Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
Benzinga
8.5
02-19Benzinga
Etsy Sells Depop to eBay for $1.2 Billion
  • Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
  • Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
  • Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
  • Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
Businesswire
1.0
02-18Businesswire
Cardio Diagnostics to Host Investor Call on February 19, 2026
  • Investor Conference Call: Cardio Diagnostics will host an investor conference call on February 19, 2026, at 3 p.m. Central Time, aimed at providing updates on the company's advancements in cardiovascular disease prevention and early detection.
  • Product Updates: The call will cover the latest clinical data and reimbursement progress for the company's existing tests, Epi+Gen CHD™ and PrecisionCHD™, showcasing its innovative capabilities in precision cardiovascular medicine.
  • Technology-Driven Approach: Cardio Diagnostics leverages artificial intelligence and genomics to make cardiovascular disease prevention, detection, and management more personalized and precise, further advancing the development and commercialization of clinical tests.
  • Risk Factors Disclosure: The company notes in its statement that its future growth strategy may face various known and unknown risks and uncertainties, which could significantly impact its financial performance.
Newsfilter
1.0
02-17Newsfilter
Cardio Diagnostics to Host Investor Conference Call
  • Investor Conference Call: Cardio Diagnostics will host an investor conference call on February 18, 2026, at 3 p.m. Central Time, aimed at providing updates on the company's advancements in cardiovascular disease prevention and early detection, particularly regarding its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™.
  • Clinical Data Updates: The call will cover recent breakthrough clinical data and reimbursement progress, indicating the company's efforts to enhance the efficiency of cardiovascular disease detection and management through its precision molecular approach.
  • Strategic Growth Initiatives: The conference will also discuss the company's strategic growth initiatives, emphasizing its market positioning and future development direction in the field of precision cardiovascular medicine, aimed at attracting more investor interest.
  • Webcast Information: Investors can participate via the provided webcast link, while telephone participants should dial the specified numbers and use the provided passcode, ensuring broad dissemination of information and engagement.

Valuation Metrics

The current forward P/E ratio for Cardio Diagnostics Holdings Inc (CDIO.O) is 0.00, compared to its 5-year average forward P/E of -3.96. For a more detailed relative valuation and DCF analysis to assess Cardio Diagnostics Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.96
Current PE
0.00
Overvalued PE
1.48
Undervalued PE
-9.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
89.74
Current PS
0.00
Overvalued PS
273.31
Undervalued PS
-93.84

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top loosers today
Intellectia · 908 candidates
Region: USPrice Change Pct: <= $-3.00
Ticker
Name
Market Cap$
top bottom
OLMA logo
OLMA
Olema Pharmaceuticals Inc
1.70B
ORIC logo
ORIC
Oric Pharmaceuticals Inc
1.54B
RVPH logo
RVPH
Reviva Pharmaceuticals Holdings Inc
20.87M
EUDA logo
EUDA
EUDA Health Holdings Ltd
27.12M
CDIO logo
CDIO
Cardio Diagnostics Holdings Inc
9.68M
COOK logo
COOK
Traeger Inc
84.24M
stocks under 10 expected to gap up today
Intellectia · 26 candidates
Price: $1.00 - $10.00Volume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEGap Pattern: GapUpPre Market Price Change: >= $3.00
Ticker
Name
Market Cap$
top bottom
JZXN logo
JZXN
Jiuzi Holdings Inc
1.66M
CDIO logo
CDIO
Cardio Diagnostics Holdings Inc
3.89M
BOXL logo
BOXL
Boxlight Corp
1.24M
TALK logo
TALK
Talkspace Inc
651.03M
ELAB logo
ELAB
PMGC Holdings Inc
1.46M
MOB logo
MOB
Mobilicom Ltd
58.61M
what stocks to short
Intellectia · 21 candidates
Short Ratio: MoreThan30PctBeta: HighRiskRsi 14: <= 40Month Price Change Pct: <= $0.00
Ticker
Name
Market Cap$
top bottom
HOOD logo
HOOD
Robinhood Markets Inc
95.24B
COIN logo
COIN
Coinbase Global Inc
61.19B
MMYT logo
MMYT
MakeMyTrip Ltd
6.22B
WIX logo
WIX
Wix.Com Ltd
4.37B
ATEC logo
ATEC
Alphatec Holdings Inc
2.53B
GETY logo
GETY
Getty Images Holdings Inc
528.14M

Whales Holding CDIO

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cardio Diagnostics Holdings Inc (CDIO) stock price today?

The current price of CDIO is 1.88 USD — it has increased 5.03

What is Cardio Diagnostics Holdings Inc (CDIO)'s business?

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

What is the price predicton of CDIO Stock?

Wall Street analysts forecast CDIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDIO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cardio Diagnostics Holdings Inc (CDIO)'s revenue for the last quarter?

Cardio Diagnostics Holdings Inc revenue for the last quarter amounts to 3.56K USD, decreased -21.21

What is Cardio Diagnostics Holdings Inc (CDIO)'s earnings per share (EPS) for the last quarter?

Cardio Diagnostics Holdings Inc. EPS for the last quarter amounts to -0.80 USD, decreased -31.03

How many employees does Cardio Diagnostics Holdings Inc (CDIO). have?

Cardio Diagnostics Holdings Inc (CDIO) has 15 emplpoyees as of May 04 2026.

What is Cardio Diagnostics Holdings Inc (CDIO) market cap?

Today CDIO has the market capitalization of 5.56M USD.